Pediatric Blood & Cancer · 2014 · 22 citations · 24 references
MedicineHematologyMolecular BiologyChemotherapyHematologic OncologyPediatric OncologyBone Marrow EvaluationHematologic Malignancy TherapyMinimal Residual DiseasePediatric LeukemiasRecurrence MonitoringBcr-abl1 Fusion GeneFusion Transcript AnalysisFusion Transcript DetectionLeukemia-associated Fusion GenesPolymerase Chain Reaction (Pcr) AssaysQuantitative Polymerase Chain ReactionRelapsed Acute Myeloid LeukemiaReverse Transcription Polymerase Chain Reaction (Rt-pcr)
BACKGROUND: To determine the prognostic significance of the detection of the minimal residual disease (MRD) in children with AML1/ETO AML, we compared the results of reverse-transcription polymerase chain reaction (RT-PCR) and quantitative reverse-transcription polymerase chain reaction (RQ-PCR). PROCEDURE: Between January 2006 and February 2013, 70 patients (≤16 years of age) with AML1/ETO AML were included in our study. Bone marrow samples were evaluated using by both RT-PCR and RQ-PCR assays. AML1/ETO transcripts were normalized to 10(5) ABL copies. RESULTS: When treated with fewer than four courses of therapy, no association was found between positive RT-PCR results and relapse. After four courses of therapy, a positive RT-PCR result was correlated with a probability of relapse. After induction chemotherapy, a >1.8 log reduction in AML1/ETO transcripts in BM determined by RQ-PCR may represent a subgroup of patients at low risk for relapse. MRD levels after consolidation (Courses 2 and 3) were also informative. CONCLUSION: Both RT-PCR and RQ-PCR can be used to detect MRD in childhood AML1/ETO AML. RQ-PCR can identify patients who are at high risk of relapse earlier than can RT-PCR.
24
Emmanuel Beillard, Niels Pallisgaard, Vincent H. J. van der Velden et al. · Leukemia · 2003 · 884 citations
John A. Liu Yin, Michelle A. O'Brien, Robert K. Hills et al. · Blood · 2012 · 419 citations